Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children (Q36391874)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 April 2012

Language	Label	Description	Also known as
English	Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children	scientific article published on 9 April 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

tetanus vaccine

1 reference

based on heuristic

inferred from title

author name string

Markus Knuf

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Yaela Baine

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Veronique Bianco

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Dominique Boutriau

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Jacqueline M Miller

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

publication date

9 April 2012

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Human Vaccines & Immunotherapeutics

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

866-872

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Meningococcal carriage by age: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Long-term protection in children with meningococcal C conjugate vaccination: lessons learned

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

A review of vaccine research and development: meningococcal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Prospects for vaccine prevention of meningococcal infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Meningococcal surrogates of protection--serum bactericidal antibody activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3495722

30 September 2017

Global epidemiology of meningococcal disease.

1 reference

https://api.crossref.org/works/10.4161%2FHV.20229

21 January 2018

Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile

1 reference

https://api.crossref.org/works/10.4161%2FHV.20229

21 January 2018

Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

1 reference

https://api.crossref.org/works/10.4161%2FHV.20229

21 January 2018

Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era

1 reference

https://api.crossref.org/works/10.4161%2FHV.20229

21 January 2018

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/22485049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

1 reference

https://pubmed.ncbi.nlm.nih.gov/22485049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22485049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age

1 reference

https://pubmed.ncbi.nlm.nih.gov/22485049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children

1 reference

https://pubmed.ncbi.nlm.nih.gov/22485049

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/HV.20229

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36391874&oldid=1629201033"